Jordi Martínez-Serra

xCELLigence system for real-time label-free monitoring of growth and viability of cell lines from hematological malignancies

Jordi Martínez-Serra, Antonio Gutiérrez, María Navarro-Palou et al. · OncoTargets and Therapy · 2014 · 81 citations · Full text

Life Sciences, Cell Biology, Oncology +15

Randomized Phase II Study of Trabectedin and Doxorubicin Compared With Doxorubicin Alone as First-Line Treatment in Patients With Advanced Soft Tissue Sarcomas: A Spanish Group for Research on Sarcoma Study

Javier Martín‐Broto, Antonio López–Pousa, Xavier García del Muro et al. · Journal of Clinical Oncology · 2016 · 74 citations

Medicine, Oncology, Pharmacology +13

Prognostic time dependence of deletions affecting codons 557 and/or 558 of KIT gene for relapse-free survival (RFS) in localized GIST: a Spanish Group for Sarcoma Research (GEIS) Study

Javier Martín‐Broto, Antonio Gutiérrez, José Antonio López‐Guerrero et al. · Annals of Oncology · 2010 · 72 citations

Medicine, Genetics, Oncology +11

New prognosis score including absolute lymphocyte/monocyte ratio, red blood cell distribution width and beta‐2 microglobulin in patients with diffuse large B‐cell lymphoma treated with R‐CHOP: Spanish Lymphoma Group Experience (GELTAMO)

Leyre Bento, Antonio Díaz‐López, Gilberto Barranco-Lampón et al. · British Journal of Haematology · 2019 · 67 citations · Full text

Medicine, Hematology, Oncology +14

Assessment of Safety and Efficacy of Combined Trabectedin and Low-Dose Radiotherapy for Patients With Metastatic Soft-Tissue Sarcomas

Javier Martín‐Broto, Nadia Hindi, Antonio López–Pousa et al. · JAMA Oncology · 2020 · 45 citations · Full text

Medicine, Oncology, Pharmacotherapy +14